Online inquiry

IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5082MR)

This product GTTS-WQ5082MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2RA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001161529.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1438
UniProt ID P15509
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5082MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10872MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ7220MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ6411MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ6143MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ13479MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ3193MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ15197MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ3413MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aALB03
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW